Dare Bioscience Inc has a consensus price target of $6.5, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Brookline Capital, and HC Wainwright & Co. on May 15, 2024, May 15, 2024, and May 1, 2024. With an average price target of $5 between HC Wainwright & Co., Brookline Capital, and HC Wainwright & Co., there's an implied 1134.26% upside for Dare Bioscience Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/15/2024 | Buy Now | 1381.12% | HC Wainwright & Co. | Douglas Tsao | → $6 | Reiterates | Buy → Buy | Get Alert |
05/15/2024 | Buy Now | 640.56% | Brookline Capital | Kemp Dolliver | → $3 | Upgrade | Hold → Buy | Get Alert |
05/01/2024 | Buy Now | 1381.12% | HC Wainwright & Co. | Douglas Tsao | → $6 | Reiterates | Buy → Buy | Get Alert |
04/17/2024 | Buy Now | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
04/01/2024 | Buy Now | 1381.12% | HC Wainwright & Co. | Douglas Tsao | → $6 | Reiterates | Buy → Buy | Get Alert |
11/10/2023 | Buy Now | 1381.12% | HC Wainwright & Co. | Douglas Tsao | $7 → $6 | Maintains | Buy | Get Alert |
08/11/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | Buy → Buy | Get Alert |
07/13/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | Buy → Buy | Get Alert |
06/06/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | → Buy | Get Alert |
05/22/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | Buy → Buy | Get Alert |
03/31/2023 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | → $7 | Reiterates | → Buy | Get Alert |
12/13/2022 | Buy Now | 1627.97% | HC Wainwright & Co. | Douglas Tsao | $6 → $7 | Maintains | Buy | Get Alert |
12/01/2022 | Buy Now | 1381.12% | JonesTrading | Catherine Novack | → $6 | Initiates | → Buy | Get Alert |
04/01/2022 | Buy Now | 1381.12% | HC Wainwright & Co. | Douglas Tsao | $5 → $6 | Maintains | Buy | Get Alert |
06/30/2021 | Buy Now | 2615.38% | Roth Capital | Zegbeh Jallah | — | Maintains | Buy | Get Alert |
The latest price target for Dare Bioscience (NASDAQ: DARE) was reported by HC Wainwright & Co. on May 15, 2024. The analyst firm set a price target for $6.00 expecting DARE to rise to within 12 months (a possible 1381.12% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Dare Bioscience (NASDAQ: DARE) was provided by HC Wainwright & Co., and Dare Bioscience reiterated their buy rating.
The last upgrade for Dare Bioscience Inc happened on May 15, 2024 when Brookline Capital raised their price target to $3. Brookline Capital previously had a hold for Dare Bioscience Inc.
The last downgrade for Dare Bioscience Inc happened on April 17, 2024 when Brookline Capital changed their price target from N/A to N/A for Dare Bioscience Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dare Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dare Bioscience was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
While ratings are subjective and will change, the latest Dare Bioscience (DARE) rating was a reiterated with a price target of $0.00 to $6.00. The current price Dare Bioscience (DARE) is trading at is $0.41, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.